Abstract
Pegylated liposomal doxorubicin (PLD) is a first line treatment approved for breast and ovarian cancers, multiple myeloma, and AIDS-related Kaposi sarcoma. Immediate hypersensitivity reactions (HSR) have been reported in 3-11% of patients2, but less than 1% are severe reactions that presented in the first minutes of infusion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
